Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 17;8(1):111.
doi: 10.3390/jcm8010111.

Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study

Joon-Hyop Lee  1 , Jiyoung Ahn  2 , Won Seo Park  3 , Eun Kyung Choe  4 , Eunyoung Kim  5 , Rumi Shin  6 , Seung Chul Heo  7 , Sohee Jung  8 , Kwangsoo Kim  9 , Young Jun Chai  10 , Heejoon Chae  11
Affiliations

Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study

Joon-Hyop Lee et al. J Clin Med. .

Abstract

Background: We investigated the associations between v-Raf murine sarcoma viral oncogene homolog B1 (BRAFV600E, henceforth BRAF) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and colorectal cancer (CRC) prognosis, using The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GSE39582) datasets.

Materials and methods: The effects of BRAF and KRAS mutations on overall survival (OS) and disease-free survival (DFS) of CRC were evaluated.

Results: The mutational status of BRAF and KRAS genes was not associated with overall survival (OS) or DFS of the CRC patients drawn from the TCGA database. The 3-year OS and DFS rates of the BRAF mutation (+) vs. mutation (-) groups were 92.6% vs. 90.4% and 79.7% vs. 68.4%, respectively. The 3-year OS and DFS rates of the KRAS mutation (+) vs. mutation (-) groups were 90.4% vs. 90.5% and 65.3% vs. 73.5%, respectively. In stage II patients, however, the 3-year OS rate was lower in the BRAF mutation (+) group than in the mutation (-) group (85.5% vs. 97.7%, p <0.001). The mutational status of BRAF genes of 497 CRC patients drawn from the GSE39582 database was not associated with OS or DFS. The 3-year OS and DFS rates of BRAF mutation (+) vs. mutation (-) groups were 75.7% vs. 78.9% and 73.6% vs. 71.1%, respectively. However, KRAS mutational status had an effect on 3-year OS rate (71.9% mutation (+) vs. 83% mutation (-), p = 0.05) and DFS rate (66.3% mutation (+) vs. 74.6% mutation (-), p = 0.013).

Conclusions: We found no consistent association between the mutational status of BRAF nor KRAS and the OS and DFS of CRC patients from the TCGA and GSE39582 databases. Studies with longer-term records and larger patient numbers may be necessary to expound the influence of BRAF and KRAS mutations on the outcomes of CRC.

Keywords: BRAF; KRAS; colorectal cancer; disease-free survival; overall survival.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1
Effect of BRAF mutation on (a) 3-year overall survival and (b) 3-year disease-free survival from the The Cancer Genome Atlas (TCGA) database and on (c) 3-year overall survival and (d) 3-year disease-free survival from the Gene Expression Omnibus (GSE39582) database of colorectal cancer patients of all stages.
Figure 2
Figure 2
Effect of BRAF mutation on (a) 3-year overall survival and (b) 3-year disease-free survival from the The Cancer Genome Atlas (TCGA) database of colorectal cancer stage II patients.
Figure 3
Figure 3
Effect of BRAF mutation on (a) 3-year overall survival and (b) 3-year disease-free survival from the GSE39582 database of colorectal cancer stage III patients.
Figure 4
Figure 4
Effect of KRAS mutation on (a) 3-year overall survival and (b) 3-year disease-free survival from the The Cancer Genome Atlas (TCGA) database and on (c) 3-year overall survival and (d) 3-year disease-free survival from the GSE39582 database of colorectal cancer patients of all stages.
Figure 5
Figure 5
Effect of KRAS mutation on (a) 3-year overall survival and (b) 3-year disease-free survival from the GSE39582 database of colorectal cancer stage III patients.
See this image and copyright information in PMC

References

    1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Brenner H., Kloor M., Pox C.P. Colorectal cancer. Lancet. 2014;383:1490–1502. doi: 10.1016/S0140-6736(13)61649-9. - DOI - PubMed
    1. Amin M.B., Edge S., Greene F., Byrd D.R., Brookland R.K., Washington M.K., Gershenwald J.E., Compton C.C., Hess K.R., Sullivan D.C., et al. AJCC Cancer Staging Manual. 8th ed. Springer; New York, NY, USA: 2017. pp. XVII, 1032.
    1. Huang Z., Duan H., Li H. Identification of Gene Expression Pattern Related to Breast Cancer Survival Using Integrated TCGA Datasets and Genomic Tools. Biomed. Res. Int. 2015;2015:878546. doi: 10.1155/2015/878546. - DOI - PMC - PubMed
    1. Cancer Genome Atlas Research Network Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–690. doi: 10.1016/j.cell.2014.09.050. - DOI - PMC - PubMed

LinkOut - more resources